Melbourne Clinical Trials

Inhalation Study (MAD)

The purpose of this study is to test a potential new treatment to lower the risk of rejection for people who have had a lung transplant.

9 nights
1 call visits

The purpose of this study is to test how changing the form of administration of an already approved medication affects how it is metabolised in the body. The medication, called Tacrolimus, is currently approved in multiple countries for patients who have received a lung transplant, and is normally given via a tablet or injection. In this study, the medication is given via an inhaler device (similar to an asthma pump) to healthy volunteers. Inhalation of this medication has previously been tested in a group of 20 healthy volunteers and was found to be well tolerated with no significant side effects.

The trial has been approved by an independent ethics committee and you will be reimbursed for your time.

Call us on 1800 243 733 to discuss your eligibility today!

Eligibility

Biological Sex Healthy males or females of non-childbearing potential (i.e. surgically sterile or post-menopausal)
Age 18 – 59 years old
BMI 18 – 32 kg/m²
Body Weight 50 – 120kg
Medication Not taking any
Medical History Nothing significant
Smoking History Non-smokers (no smoking within the past 3 months)